IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v19y2018i8d10.1007_s10198-018-0961-7.html
   My bibliography  Save this article

Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records

Author

Listed:
  • Marc Casajuana

    (Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)
    Universitat Autònoma de Barcelona)

  • Maria Giner-Soriano

    (Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)
    Universitat Autònoma de Barcelona
    Institut Català de la Salut, Departament de Salut)

  • Albert Roso-Llorach

    (Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)
    Universitat Autònoma de Barcelona)

  • Cristina Vedia

    (Universitat Autònoma de Barcelona
    Institut Català de la Salut)

  • Concepció Violan

    (Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)
    Universitat Autònoma de Barcelona)

  • Rosa Morros

    (Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)
    Universitat Autònoma de Barcelona
    Institut Català de la Salut, Departament de Salut
    UICEC IDIAP Jordi Gol)

Abstract

Atrial fibrillation (AF) is the most common chronic arrhythmia, with increasing healthcare and economic burden and a prevalence which increases with progressive ageing. This study aims to describe overall annual costs per patient for management of non-valvular AF in a primary healthcare (PHC) setting and compare these costs between the groups of patients treated with vitamin K antagonists, antiplatelets or non-treated through a population-based study conducted with electronic health records. We analysed annual costs per person of 19,787 patients in 2012; PHC visits, hospital admissions, AF-related events requiring hospital admission, referrals to secondary specialists, sick leave, diagnostic tests and laboratory tests at PHC level, including INR determinations performed in PHC, and drug therapy. Higher costs of AF management were associated with increasing age, male sex, stroke and bleeding risks, comorbidities and occurrence of events associated to AF. The sensitivity analyses conducted showed that PHC visits and hospitalizations represented the most important part of overall costs for all patients.

Suggested Citation

  • Marc Casajuana & Maria Giner-Soriano & Albert Roso-Llorach & Cristina Vedia & Concepció Violan & Rosa Morros, 2018. "Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(8), pages 1129-1136, November.
    • Handle: RePEc:spr:eujhec:v:19:y:2018:i:8:d:10.1007_s10198-018-0961-7
    DOI: 10.1007/s10198-018-0961-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-018-0961-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-018-0961-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:19:y:2018:i:8:d:10.1007_s10198-018-0961-7. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.